

UROPLASTY INC  
Form 8-K  
December 16, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**Date of Report: December 16, 2004**

**UROPLASTY, INC.**

(Exact name of registrant as specified in charter)

**000-20989**

---

**41-1719250**

---

(Commission File No.)

(IRS Employer Identification  
No.)

**Minnesota**

---

(State or other jurisdiction of incorporation or organization)

**2718 Summer Street NE  
Minneapolis, Minnesota 55413-2820**

---

(Address of principal executive offices)

**612-378-1180**

---

(Registrant's telephone number, including area code)

**Not Applicable**

---

(Former Name and Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 of the Securities Act (17 CFR 230.425)

Edgar Filing: UROPLASTY INC - Form 8-K

- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**TABLE OF CONTENTS**

Item 7.01 Regulation FD Disclosure

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

Press Release

---

**Table of Contents**

**Item 7.01 Regulation FD Disclosure**

On December 16, 2004, Uroplasty, Inc. announced that it had entered into a letter of intent with CystoMedix, Inc., a Minnesota corporation, pursuant to which Uroplasty expressed its intention to pursue an acquisition of CystoMedix.

A copy of Uroplasty's press release announcing its intent to acquire CystoMedix is attached as an exhibit to this report and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits:

99.1 Press Release, dated December 16, 2004

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: December 16, 2004

UROPLASTY, INC.

By: /s/ DANIEL G. HOLMAN  
Daniel G. Holman  
President, Chief Executive Officer and  
Chief Financial Officer

2

---

**Table of Contents**

**EXHIBIT INDEX**

Exhibit 99.1 Press Release, dated December 16, 2004

3